Who owns Monte Rosa Therapeutics, Inc. (GLUE)? Elite investor 13F holders
3 tracked elite investors reported holding Monte Rosa Therapeutics, Inc as of 2026-06-30, including Alphabet, Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Alphabet | MONTE ROSA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-07 00:00:00 | 9013871.00 USD | 372474.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | MONTE ROSA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 2480500.00 USD | 102500.000000 | Shares | reduce | Original filing |
| D.E. Shaw | MONTE ROSA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 4163683.00 USD | 172053.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.